Huonslab, a subsidiary of Huons Group, introduced its proprietary HyDIFFUZE™ formulation platform and innovative drug pipeline at the world’s largest biotechnology exhibition, BIO International Convention 2025, held on June 16 in Boston, Massachusetts.

HyDIFFUZE™ is a platform technology that uses human hyaluronidase to convert intravenous (IV) antibody therapeutics into subcutaneous (SC) formulations. Hyaluronidase acts as a dispersion agent by breaking down hyaluronic acid under the skin, facilitating effective SC drug delivery.

Huonslab’s lead candidate, HLB3-002, is manufactured using a patented high-purity, high-yield process that avoids fragmented byproducts. The product shares an identical amino acid sequence with endogenous human hyaluronidase, offering a favorable safety profile. In vivo studies confirmed that HLB3-002 demonstrated comparable pharmacokinetics and dispersion efficacy to existing SC formulations.

HLB3-002 is being developed as a proprietary alternative to Halozyme Therapeutics’ Hylenex®. The drug is currently in a pivotal Phase 1 clinical trial in Korea, with patient enrollment completed last month. Huonslab aims to submit a Biologics License Application (BLA) to the Korean Ministry of Food and Drug Safety (MFDS) in the second half of this year, pending trial results.

Dr. Byung Ha Lee, Chief Business Officer at Huonslab, stated, “Presenting HLB3-002 and our HyDIFFUZE™ platform at BIO USA has opened doors for potential technology transfers and global collaborations. Its versatility—ranging from plastic surgery and aesthetics to pain and inflammation management—has attracted significant interest from international pharmaceutical partners.”